Mortality in<unk> -infected patients with cardiomyopathy is increased independently of CD4 count, age, sex, and<unk>  risk group. The therapy is similar to therapy for non-ischemic cardiomyopathy: after medical therapy is begun, serial echocardiographic studies should be performed at 4-months intervals. If function continues to worsen or the clinical course deteriorates, a biopsy should be considered. HAART has reduced the incidence of myocarditis thus reducing the prevalence of<unk>  by about 30% in developed countries. However, the prevalence in developing countries is 32% and increasing as HAART is scarce – not to mention the effects of other risk factors such as high cholesterol and lipid diet. IVIGs can also help patients with<unk><unk>  myocarditis as mentioned earlier.
HIV associated cardiomyopathy
Viral cardiomyopathy
Coxsackievirus-induced cardiomyopathy
Amyloid cardiomyopathy
Cardiac amyloidosis
Alcoholic cardiomyopathy
Eosinophilic myocarditis
Idiopathic giant-cell myocarditis